#Ireland #Dublin #Jazz Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals to Present at 2025 AAN Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is set to showcase its groundbreaking neuroscience research at the 77th Annual American Academy of Neurology (AAN) Meeting, taking place from April 5-9, 2025, in San Diego. The company will feature seven pivotal abstracts from its extensive neuroscience portfolio, underscoring its commitment to advancing the treatment of complex neurological disorders.

Key Highlights from the Research

The focus of this year's presentations revolves around two major products: Xywav® (calcium, magnesium, potassium, and sodium oxybates) and Epidiolex® (cannabidiol). Recent findings from the open-label Phase 4 DUET trial have highlighted Xywav's efficacy in treating excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy or idiopathic hypersomnia.

1. Xywav Clinical Outcomes:
The DUET trial revealed that patients experienced statistically significant reductions in Epworth Sleepiness Scale (ESS) scores after treatment with Xywav. Improvements in deep sleep quality and decreases in night awakenings were also noted, showcasing the potential of Xywav to significantly enhance patient quality of life.

2. Real-World Data on Epidiolex:
A comprehensive analysis of treatment patterns emerged, revealing an impressive near 70% persistence rate among new Epidiolex patients after one year. This emphasizes the necessity of dose optimization for effective long-term outcomes, with insights indicating that increased dosages correlate with reduced rates of discontinuation.

Commitment to Neuroscience

Dr. Sarah Akerman, head of neuroscience global medical and scientific affairs at Jazz Pharmaceuticals, commented, "Our presentations at this year's AAN Annual Meeting reinforce our ongoing commitment to addressing debilitating neurological disorders, which often have limited treatment options. By continuously generating data on Xywav and Epidiolex, we aim to better reflect the lived experiences of patients and their needs.

The company's research not only focuses on drug efficacy but also addresses the broader implications of treatment on daily functioning and quality of life – critical components for patients enduring chronic neurological conditions.

Presentations Breakdown

• - Presentation: Self-Reported Cognitive Complaints and Work Productivity After Xywav Treatment

- Lead Author: LDSchneider
- Session: April 8, 2025, 8:00 AM - 9:00 AM

• - Presentation: Effectiveness and Safety of Low-Sodium Oxybate in Narcolepsy Patients

- Lead Author: LDSchneider
- Session: April 8, 2025, 5:00 PM - 6:00 PM

• - Presentation: Insights from US Specialty Pharmacy Data on Epidiolex

- Lead Author: G Pohl
- Session: April 9, 2025, 11:45 AM - 12:45 PM

Concluding Thoughts

Jazz Pharmaceuticals remains dedicated to pioneering advancements in the treatment of complex neurological disorders. As they prepare for this pivotal conference, their research signifies a determined effort to not only enhance medication efficacy but also to support patients living with challenging conditions.

For more information on the presented research, please refer to the abstracts available at AAN 2025.

Jazz Pharmaceuticals continues to strive for excellence in improving the lives of patients and their families, ensuring that innovative treatments are developed with their needs at the forefront.